Inclusion Criteria:

- Male or female patients, age 18 years or older

- Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic,
accelerated, or blast phase

- Patients will have either failed, demonstrated intolerance, or a combination of prior
failure and intolerance, to prior treatments with at least two tyrosine kinase
inhibitors (TKI's). Failure of TKI treatment may either be primary (never achieved a
response) or secondary resistance (loss of response).

- Acceptable Renal and Liver Function

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

- Sexually active patients and their partners must use an effective double barrier
method of contraception

Exclusion Criteria:

- New York Heart Association classification (NYHA) class III or IV heart disease,
active ischemia or any other uncontrolled cardiac condition

- Myocardial infarction in the previous 12 weeks.

- Other concurrent illness which would preclude study conduct and assessment

- uncontrolled and active infection, and positive HIV or positive HTLV I/II status,
whether on treatment or not.

- Pregnant or lactating.

- Any medical or psychiatric condition, which may compromise the ability to give
written informed consent or to comply with the study protocol.

- Lymphoid Ph+ blast crisis

- Patient is enrolled in another clinical investigation within 30 days of enrollment or
is receiving another investigational agent